SCHEMBL21458181

SCHEMBL21458181

CCOc1cc(-c2ccc(Cn3ncc4c(Cl)ccc(C(=O)NC5CC6(C5)CC(C(=O)O)C6)c43)cc2)ccn1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.39
CSNK2A2 P19784 6/20 0.36
CSNK2A1 P68400 6/20 0.36
S1PR1 P21453 1/20 0.33
S1PR5 Q9H228 1/20 0.33
CNR2 P34972 5/20 0.33
PTGER2 P43116 1/20 0.33
SSTR5 P35346 3/20 0.33
SSTR1 P30872 1/20 0.33
HRH1 P35367 1/20 0.33
ROCK2 O75116 1/20 0.32
APOBEC3A P31941 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
BMPR1B O00238 1/20 0.31
BMPR1A P36894 1/20 0.31
TGFBR1 P36897 1/20 0.31
ACVRL1 P37023 1/20 0.31
ACVR1 Q04771 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31203684 1.00 PTGER4 (0.39) PTGER4CSNK2A2CSNK2A1S1PR1S1PR5
SCHEMBL21481839 1.00 PTGER4 (0.39) PTGER4CSNK2A2CSNK2A1S1PR1S1PR5
SCHEMBL31203592 0.94 CSNK2A2 (0.42) PTGER4CSNK2A2CSNK2A1CNR2ROCK2
SCHEMBL21458227 0.94 CSNK2A2 (0.42) PTGER4CSNK2A2CSNK2A1CNR2ROCK2
SCHEMBL31203186 0.91 CNR2 (0.40) CSNK2A2CSNK2A1CNR2BMPR1BBMPR1A
SCHEMBL21481838 0.91 CSNK2A2 (0.45) CSNK2A2CSNK2A1CNR2SSTR5SSTR1
SCHEMBL21481909 0.88 PTGER4 (0.36) PTGER4CSNK2A2CSNK2A1S1PR1S1PR5
SCHEMBL21458143 0.88 PTGER4 (0.36) PTGER4CSNK2A2CSNK2A1S1PR1S1PR5
SCHEMBL21458208 0.87 CSNK2A2 (0.37) PTGER4CSNK2A2CSNK2A1S1PR1S1PR5
SCHEMBL21481954 0.87 CSNK2A2 (0.37) PTGER4CSNK2A2CSNK2A1S1PR1S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3781550-B1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2024-10-30 EP claimed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 US claimed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 US claimed
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-12215093-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2025-02-04 US disclosed
EP-3781550-B1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2024-10-30 EP disclosed
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2024-05-09 US disclosed
US-11472789-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2022-10-18 US disclosed
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 US disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 US disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 PTGER4 1/4885CSNK2A2 574/4885CSNK2A1 711/4885
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 PTGER4 1/4885CSNK2A2 574/4885CSNK2A1 711/4885
US-11472789-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 PTGER4 1/4885CSNK2A2 574/4885CSNK2A1 711/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 PTGER4 1/4885CSNK2A2 574/4885CSNK2A1 711/4885
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 PTGER4 1/4885CSNK2A2 574/4885CSNK2A1 711/4885
US-12215093-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 PTGER4 1/4885CSNK2A2 574/4885CSNK2A1 711/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 PTGER4 1/4885CSNK2A2 574/4885CSNK2A1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.